XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended March 31,
 20242023
Net product revenue$7,796.5 $6,238.2 
Collaboration and other revenue
971.5 721.8 
Revenue$8,768.0 $6,960.0 
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
 20242023
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Diabetes and obesity:
Mounjaro®
$1,520.4 $286.2 $1,806.5 $536.4 $32.0 $568.5 
Trulicity®
1,081.9 374.4 1,456.3 1,547.4 429.7 1,977.1 
Jardiance(1)
368.2 318.3 686.5 329.4 248.1 577.5 
Humalog® (2)
338.3 200.4 538.7 271.6 189.3 460.9 
Zepbound®
517.4 — 517.4 — — — 
Humulin®
153.1 53.1 206.2 198.8 53.2 252.0 
Basaglar® (3)
83.2 74.3 157.6 135.4 73.9 209.3 
Other diabetes and obesity27.5 96.3 123.8 56.0 89.2 145.1 
Total diabetes and obesity4,090.0 1,403.0 5,493.0 3,075.0 1,115.4 4,190.4 
Oncology:
Verzenio®
638.2 412.1 1,050.3 461.1 289.8 750.9 
Cyramza®
107.2 122.6 229.9 100.6 136.1 236.8 
Erbitux®
132.1 12.5 144.6 118.8 11.1 129.9 
Tyvyt®
— 116.7 116.7 — 61.0 61.0 
Other oncology120.8 147.8 268.5 72.9 104.6 177.4 
Total oncology998.3 811.7 1,810.0 753.4 602.6 1,356.0 
Immunology:
Taltz®
347.1 257.0 604.1 312.2 214.8 527.0 
Olumiant®
46.3 171.0 217.4 42.3 186.5 228.9 
Other immunology3.8 8.8 12.5 — 22.0 22.0 
Total immunology397.2 436.8 834.0 354.5 423.3 777.8 
Neuroscience:
Emgality®
125.0 100.7 225.7 108.7 45.6 154.3 
Other neuroscience38.2 125.2 163.4 35.8 170.4 206.2 
Total neuroscience163.2 225.9 389.1 144.5 216.0 360.5 
Other:
Cialis®
5.9 133.4 139.3 7.6 92.7 100.3 
Forteo®
21.7 39.5 61.3 70.7 51.7 122.3 
Other18.1 23.3 41.3 30.5 22.2 52.8 
Total other45.7 196.2 241.9 108.7 166.6 275.3 
Revenue$5,694.4 $3,073.7 $8,768.0 $4,436.2 $2,523.9 $6,960.0 
Numbers may not add due to rounding.
(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(2) Humalog revenue includes insulin lispro.
(3) Basaglar revenue includes Rezvoglar®.
The following table summarizes revenue by geographical area:
Three Months Ended March 31,
20242023
Revenue(1):
U.S.$5,694.4 $4,436.2 
Europe1,440.7 1,090.9 
China376.2 372.7 
Japan363.9 387.2 
Other foreign countries892.9 673.1 
Revenue$8,768.0 $6,960.0 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer or other party.
Schedule of Amounts Recorded for Contract Liabilities
The following table summarizes contract liability balances:
 March 31, 2024December 31, 2023
Contract liabilities$186.7 $193.6